Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In Ldlr Null Mice
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insulin-resistant states, such as obesity and type 2 diabetes, contribute substantially to accelerated atherogenesis. Null mutations of myostatin (Mstn) are associated with increased muscle mass and decreased fat mass. In this study, we determined whether Mstn disruption could prevent the development of insulin resistance, proatherogenic dyslipidemia, and atherogenesis. RESEARCH DESIGN AND METHODS: C57BL/6 Ldlr−/− mice were cross-bred with C57BL/6 Mstn−/− mice for >10 generations to generate Mstn−/−/Ldlr−/− double-knockout mice. The effects of high-fat/high-cholesterol diet on body composition, plasma lipids, systemic and tissue-specific insulin sensitivity, hepatic steatosis, as well as aortic atheromatous lesion were characterized in Mstn−/−/Ldlr−/− mice in comparison with control Mstn+/+/Ldlr−/− mice. RESULTS: Compared with Mstn+/+/Ldlr−/− controls, Mstn−/−/ Ldlr−/− mice were resistant to diet-induced obesity, and had greatly improved insulin sensitivity, as indicated by 42% higher glucose infusion rate and 90% greater muscle [3H]-2-deoxyglucose uptake during hyperinsulinemic-euglycemic clamp. Mstn−/−/Ldlr−/− mice were protected against diet-induced hepatic steatosis and had 56% higher rate of hepatic fatty acid β-oxidation than controls. Mstn−/−/Ldlr−/− mice also had 36% lower VLDL secretion rate and were protected against diet-induced dyslipidemia, as indicated by 30–60% lower VLDL and LDL cholesterol, free fatty acids, and triglycerides. Magnetic resonance angiography and en face analyses demonstrated 41% reduction in aortic atheromatous lesions in Ldlr−/− mice with Mstn deletion. CONCLUSIONS: Inactivation of Mstn protects against the development of insulin resistance, proatherogenic dyslipidemia, and aortic atherogenesis in Ldlr−/− mice. Myostatin may be a useful target for drug development for prevention and treatment of obesity and its associated type 2 diabetes and atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Musarò, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E. R., L Sweeney, H., & Rosenthal, N. (2001) · Nature Genetics · doi:10.1038/84839 · Cited by 1,137 · cited 1×
“Indeed, mice with increased muscle oxidation, such as those overexpressing IGF-1 (33) or Akt-1 (11) in skeletal muscles, have little fat deposition.”
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505 · cited 3×
“Disruption of myostatin gene has also been shown to prevent the development of obesity (6).”
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
FGF21 is an Akt‐regulated myokine
Izumiya, Y., Bina, H. A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., & Walsh, K. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.021 · Cited by 415 · cited 1×
“Other myokines, such as fibroblast growth factor-21 (Fgf-21) and follistatin like-1 (Fstl-1), may also have salutary effects on fat accumulation and insulin sensitivity (37,38).”
Guo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004937 · Cited by 402 · cited 3×
“Similar to systemic loss of Mstn, inhibition of myostatin signaling exclusively in the skeletal muscle was sufficient to resist diet-induced obesity and insulin resistance (10).”
Fast/Glycolytic Muscle Fiber Growth Reduces Fat Mass and Improves Metabolic Parameters in Obese Mice
Izumiya, Y., Hopkins, T., Morris, C., Sato, K., Zeng, L., Viereck, J., Hamilton, J. A., Ouchi, N., LeBrasseur, N. K., & Walsh, K. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.003 · Cited by 395 · cited 4×
“In addition, it is possible that acquisition of hypermuscularity by itself could lead to leanness (11).”
InfluentialSelf-citationAbu-Elheiga, L., Oh, W., Kordari, P., & Wakil, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1733877100 · Cited by 389
Ouchi, N., Oshima, Y., Ohashi, K., Higuchi, A., Ikegami, C., Izumiya, Y., & Walsh, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803440200 · Cited by 338 · cited 1×
“Other myokines, such as fibroblast growth factor-21 (Fgf-21) and follistatin like-1 (Fstl-1), may also have salutary effects on fat accumulation and insulin sensitivity (37,38).”
Cited by
Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review
White, T. A., & LeBrasseur, N. K. (2014) · Gerontology · doi:10.1159/000356740 · Cited by 191
Guo, W., Wong, S., Li, M., Liang, W., Liesa, M., Serra, C., Jasuja, R., Bartke, A., Kirkland, J. L., Shirihai, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051180 · Cited by 59
Self-citationBuilding muscle, browning fat and preventing obesity by inhibiting myostatin
LeBrasseur, N. K. (2012) · Diabetologia · doi:10.1007/s00125-011-2361-8 · Cited by 46
Perry, C. A., Van Guilder, G. P., & Butterick, T. A. (2022) · BMC Nutrition · doi:10.1186/s40795-022-00516-9 · Cited by 16
Post-exercise changes in myostatin and actRIIB expression in obese insulin-resistant rats
Bueno, P. G., Bassi, D., Contrera, D. G., Carnielli, H. M., Silva, R. N., Nonaka, K. O., Selistre-de-Araújo, H. S., & Leal, A. M. O. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.04.006 · Cited by 13
Metadata
- Authors
- Tu, P., Bhasin, S., Hruz, P. W., Herbst, K. L., Castellani, L. W., Hua, N., Hamilton, J. A., & Guo, W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-06-09
- Volume
- 58
- Issue
- 8
- Pages
- 1739-1748
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2157467578
- Cited by
- 72
- References
- 12
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In Ldlr Null Mice. https://app.cochat.ai/papers/10.2337/db09-0349
- The paper
- Tu, P., Bhasin, S., Hruz, P. W., Herbst, K. L., Castellani, L. W., Hua, N., Hamilton, J. A., & Guo, W. (2009). Genetic Disruption of Myostatin Reduces the Development of Proatherogenic Dyslipidemia and Atherogenic Lesions In Ldlr Null Mice. Diabetes. https://doi.org/10.2337/db09-0349
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.